Johnson & Johnson is awaiting two FDA decisions after approvals for Rybrevant and Icotyde helped JNJ rise nearly 11.5% year to date. Ottava is under FDA review after a January 2026 submission, while JNJ-78934804 remains in clinical trials and might be submitted in 2027.